JP7446322B2 - アルツハイマー病を治療する方法 - Google Patents

アルツハイマー病を治療する方法 Download PDF

Info

Publication number
JP7446322B2
JP7446322B2 JP2021547654A JP2021547654A JP7446322B2 JP 7446322 B2 JP7446322 B2 JP 7446322B2 JP 2021547654 A JP2021547654 A JP 2021547654A JP 2021547654 A JP2021547654 A JP 2021547654A JP 7446322 B2 JP7446322 B2 JP 7446322B2
Authority
JP
Japan
Prior art keywords
hydroxypropyl
cyclodextrin
composition
human patient
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509358A (ja
JP2022509358A5 (https=
Inventor
フリノウ，シャロン，エイチ
テイト，ジェフリー，エル．
ファイン，エヌ．，スコット
Original Assignee
シクロ セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シクロ セラピューティクス インク filed Critical シクロ セラピューティクス インク
Publication of JP2022509358A publication Critical patent/JP2022509358A/ja
Publication of JP2022509358A5 publication Critical patent/JP2022509358A5/ja
Application granted granted Critical
Publication of JP7446322B2 publication Critical patent/JP7446322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
JP2021547654A 2018-10-29 2019-10-24 アルツハイマー病を治療する方法 Active JP7446322B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752131P 2018-10-29 2018-10-29
US62/752,131 2018-10-29
US201962885053P 2019-08-09 2019-08-09
US62/885,053 2019-08-09
PCT/US2019/057784 WO2020092107A1 (en) 2018-10-29 2019-10-24 Methods for treating alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2022509358A JP2022509358A (ja) 2022-01-20
JP2022509358A5 JP2022509358A5 (https=) 2022-10-28
JP7446322B2 true JP7446322B2 (ja) 2024-03-08

Family

ID=68583503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547654A Active JP7446322B2 (ja) 2018-10-29 2019-10-24 アルツハイマー病を治療する方法

Country Status (10)

Country Link
US (3) US11925659B2 (https=)
EP (1) EP3873604B1 (https=)
JP (1) JP7446322B2 (https=)
KR (1) KR20210084480A (https=)
CN (1) CN112996562A (https=)
BR (1) BR112021008139A2 (https=)
CA (1) CA3114021C (https=)
ES (1) ES2992137T3 (https=)
PT (1) PT3873604T (https=)
WO (1) WO2020092107A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4157290A4 (en) * 2020-06-02 2024-06-05 National University of Singapore COMPOSITIONS, THEIR USES IN THERAPY AND METHODS THEREFOR
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
EP4240486A4 (en) * 2020-11-06 2024-05-22 EIP Pharma, Inc. TREATMENT OF GALKING DYSFUNCTION IN THE CONTEXT OF A NEURODEGENERATIVE DISEASE
US12285440B2 (en) 2021-03-14 2025-04-29 Massachusetts Institute Of Technology APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia
WO2023089062A1 (en) * 2021-11-18 2023-05-25 Vib Vzw Improved gamma-secretase inhibitor screening assays
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023191425A1 (ko) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
CA3259307A1 (en) * 2022-06-13 2023-12-21 Beren Therapeutics P.B.C. SYSTEMS AND METHODS FOR MANUFACTURING HYDROXYPROPYL-BETA-CYCLODEXTRIN
EP4561566A1 (en) * 2022-07-29 2025-06-04 Anavex Life Sciences Corp. Compositions and methods for prevention of cognitive decline caused by degenerative diseases
KR20250073473A (ko) * 2022-09-30 2025-05-27 싸이클로 테라퓨틱스, 아이엔씨. 조기 알츠하이머병 치료 방법
WO2025214478A1 (zh) * 2024-04-12 2025-10-16 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500310A (ja) 2013-12-13 2017-01-05 ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ Ｈｄｌコレステロール値を上昇させることによって疾病を治療かつ／または予防する、メチルシクロデキストリンをベースとする組成物
JP2017517528A (ja) 2014-06-12 2017-06-29 ユニバーシティ オブ ノートルダム デュ ラック 神経疾患および大脳損傷の処置のための組成物および方法
US20180085392A1 (en) 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US8883494B2 (en) 2003-11-14 2014-11-11 Adil A. KHAN In vitro model for neuronal death
CN101674842A (zh) 2007-03-02 2010-03-17 普瑞芬医药有限公司 治疗阿尔茨海默氏病和痴呆的组合物和方法
MX371073B (es) 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
US20200000840A1 (en) * 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500310A (ja) 2013-12-13 2017-01-05 ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ Ｈｄｌコレステロール値を上昇させることによって疾病を治療かつ／または予防する、メチルシクロデキストリンをベースとする組成物
JP2017517528A (ja) 2014-06-12 2017-06-29 ユニバーシティ オブ ノートルダム デュ ラック 神経疾患および大脳損傷の処置のための組成物および方法
US20180085392A1 (en) 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AUTOPHAGY，2018年，14(7)，pp.1129-1154
Free Radical Biology and Medicine，2018年，120，S79, P-114
http://dx.doi.org/10.5772/intechopen.71970［検索日：２０２３年９月６日］，2017年
Human Molecular Genetics，2017年，26(5)，pp.843-859
IRYO，71(3)，2017年，pp.132-137
J. Exp. Med.，2013年，209(13)，pp.2501-2513
Journal of Drug Targeting，2009年，17(2)，pp.168-179
Journal of Pharmaceutical Sciences，2016年，105，pp.2372-2380
Molecules，2016年，21，1748 (22 pages)
Phys. Chem. Chem. Phys.，2016年，18，pp.20476-20485

Also Published As

Publication number Publication date
CN112996562A (zh) 2021-06-18
EP3873604B1 (en) 2024-08-21
CA3114021A1 (en) 2021-05-07
KR20210084480A (ko) 2021-07-07
BR112021008139A2 (pt) 2021-08-03
WO2020092107A1 (en) 2020-05-07
US20220008453A1 (en) 2022-01-13
JP2022509358A (ja) 2022-01-20
EP3873604A1 (en) 2021-09-08
CA3114021C (en) 2025-05-27
ES2992137T3 (es) 2024-12-09
PT3873604T (pt) 2024-10-22
US11925659B2 (en) 2024-03-12
US20240415871A1 (en) 2024-12-19
US20250302864A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
JP7446322B2 (ja) アルツハイマー病を治療する方法
HK1242998A1 (zh) 治疗法布里病的给药方案
EP3445369B1 (en) Vx-745 for use in the treatment of dementia
KR20250078929A (ko) 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용
EP3137097B1 (en) Treatment and prevention of alzheimer's disease (ad)
CN120051284A (zh) 用于治疗早期阿尔茨海默病的方法
EP3137094B1 (en) Treatment and prevention of alzheimer's disease (ad)
WO2020214538A1 (en) Treatment and prevention of dementia and other neurodegenerative diseases
AU2015254663B2 (en) Treatment and prevention of Alzheimer's Disease (AD)
HK40059055A (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
HK40059055B (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
US20260124236A1 (en) Methods for treating early alzheimer’s disease
CA3268619A1 (en) Methods for treating early alzheimer's disease
Sharma et al. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases
US20240016783A1 (en) Riluzole for the treatment of alzheimer's disease
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240227

R150 Certificate of patent or registration of utility model

Ref document number: 7446322

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150